 |
| Clinical Pharmacy MCQs with Answers and Explanations |
A 45-year-old lady known case hypertension since one year on the following medications: Lisinopril 5 mg orally once daily, Amlodipine 10 mg orally once daily. She was doing well and her blood pressure was controlled. In the last follow up visit, she informed her treating physician that she is planning to get pregnant.
Which of the following is the most important decision to be taken for this patient before becoming pregnant?
A. add methyldopa
B. discontinue lisinopril
C. continue same treatment in pregnancy
D. decrease lisinopril dose to 2.5 mg once daily
The correct answer is B. discontinue lisinopril.
Key Clinical Explanation
Teratogenicity of ACE Inhibitors: Lisinopril is an Angiotensin-Converting Enzyme (ACE) inhibitor. ACE inhibitors and Angiotensin Receptor Blockers (ARBs) are strictly contraindicated during pregnancy due to high risks of fetotoxicity and teratogenicity (including renal dysgenesis, oligohydramnios, skull hypoplasia, intrauterine growth restriction, and fetal demise).
Pre-conception Management: Because organogenesis occurs in the early weeks of gestation—often before a woman realizes she is pregnant—ACE inhibitors like Lisinopril must be discontinued prior to conception (or immediately upon planning/discovering pregnancy) and switched to a pregnancy-safe antihypertensive agent (such as Labetalol, Nifedipine, or Methyldopa) if pharmacological blood pressure control is still required.
Explanation of Incorrect Options
A. Add methyldopa: Methyldopa is safe in pregnancy, but adding it while keeping Lisinopril active leaves the fetus exposed to a known teratogen. The immediate essential step is stopping Lisinopril.
C. Continue same treatment in pregnancy: Continuing Lisinopril throughout pregnancy presents a major threat to fetal safety.
D. Decrease lisinopril dose to 2.5 mg once daily: Reducing the dose does not eliminate the teratogenic risk of ACE inhibitors. Complete discontinuation is required.
Clinical pearl for exams: ACE inhibitors (e.g., lisinopril) and ARBs (e.g., losartan) should be avoided during pregnancy. Common pregnancy-compatible antihypertensives include labetalol, extended-release nifedipine, and methyldopa.
Important note: Amlodipine is not generally a first-line preferred antihypertensive in pregnancy, although available evidence has not established the same degree of fetal risk as ACE inhibitors. Her treatment should be reviewed by her physician before conception.
A 45-year-old male is admitted to the hospital for craniotomy Phenytoin has been prescribed to him after the surgery. Before initiation of the drug the pharmacist suggested to do pharmacogenetics test and the results revealed that the patient carries the HLA-B*58:01 allele.
Which of the following adverse effects is associated with this patient's allele type?
A. bleeding
B. high blood pressure
C. increased risk of jaundice
D. severe cutaneous reaction
The correct answer is D. severe cutaneous reaction.
(Best available answer: This is the adverse effect associated with HLA-B*58:01, but the classic drug association is allopurinol, not phenytoin. For a scientifically accurate board-style question, replace HLA-B*58:01 with HLA-B*15:02 if the intended drug is phenytoin.)
Key Clinical Explanation
HLA Alleles and Severe Cutaneous Adverse Reactions (SCARs): Specific human leukocyte antigen (HLA) alleles are strongly associated with drug-induced Severe Cutaneous Adverse Reactions (SCARs)—including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
Pharmacogenomic Risk:
HLA-B*58:01 is primarily associated with severe cutaneous reactions caused by allopurinol.
HLA-B*15:02 (and HLA-A*31:01) is strongly associated with severe cutaneous reactions induced by aromatic antiepileptics such as phenytoin, carbamazepine, and lamotrigine.
Regardless of the specific drug cross-linkage being tested in genetic screening (e.g., HLA testing prior to aromatic antiepileptics or uric acid-lowering therapy), presence of risk HLA-B variants is used to screen for severe cutaneous reactions.
Explanation of Incorrect Options
A. Bleeding: Associated with coagulopathies, antiplatelet/anticoagulant drugs, or CYP2C9 variants affecting warfarin metabolism, not HLA-B alleles.
B. High blood pressure: Not a recognized HLA allele-associated adverse reaction.
C. Increased risk of jaundice: While drug-induced liver injury can occur in conditions like DRESS syndrome, HLA-B marker testing before initiating these agents is specifically indicated to prevent severe cutaneous reactions (SJS/TEN/DRESS).
A 33-year-old woman with no underlying medical condition came to a clinic with complaints of dysuria, urinary frequency and urgency, and suprapubic tenderness. She was diagnosed with urinary tract infection and treated with trimethoprim/sulfamethoxazole.
Which of the following is an objective parameter to assess the effectiveness of drug therapy?
A. resolution of back pain
B. decrease in cough frequency
C. improved ability to concentrate
D. normalization of white blood cells
The correct answer is D. normalization of white blood cells.
Key Clinical Explanation
Subjective vs. Objective Parameters:
Objective parameters are measurable, quantifiable, and independently verifiable laboratory data or clinical measurements (e.g., white blood cell [WBC] count, urinalysis, urine culture, temperature, blood pressure).
Subjective parameters are qualitative self-reported symptoms described directly by the patient (e.g., pain levels, cough severity, difficulty concentrating, feelings of urgency or dysuria).
Assessing UTI Treatment Outcome:
In an infection such as a urinary tract infection (UTI), a decrease and normalization of white blood cells (e.g., resolution of leukocytosis on complete blood count or reduction of pyuria/WBCs on urinalysis) serves as an objective laboratory indicator that the bacterial infection is clearing and antibiotic therapy is effective.
Explanation of Incorrect Options
A. Resolution of back pain: Pain is a subjective symptom reported by the patient, not a direct objective laboratory/clinical measurement.
B. Decrease in cough frequency: Cough is unrelated to a urinary tract infection and is primarily a subjective symptom report.
C. Improved ability to concentrate: This is a subjective self-report and is unrelated to a standard uncomplicated UTI.
Exam pearl: Subjective outcomes include pain, urgency, and dysuria reported by the patient. Objective outcomes include laboratory values, vital signs, and measurable clinical findings.
Clinical note: In uncomplicated UTI, symptom resolution is usually the primary measure of treatment success. A repeat WBC count is not routinely necessary in an otherwise healthy woman whose symptoms resolve.
Which of the following osteoporosis drugs can cause esophageal ulcers?
A. denosumab
B. teriparatide
C. alendronate
D. zelodronic acid
The correct answer is C. alendronate.
Key Clinical Explanation
Oral Bisphosphonates and Upper GI Toxicity: Alendronate is an oral bisphosphonate commonly prescribed for the prevention and treatment of osteoporosis. Oral bisphosphonates can cause direct chemical mucosal irritation, leading to esophagitis, severe esophageal ulcers, erosion, and strictures.
Administration Guidelines: To minimize the risk of severe esophageal injury, patients taking oral alendronate are instructed to:
✒Swallow the tablet whole with a full glass (6 to 8 ounces) of plain water.
✒Take it first thing in the morning on an empty stomach.
✒Remain sitting or standing upright for at least 30 minutes after ingestion and until after their first food of the day.
Explanation of Incorrect Options
A. Denosumab: A monoclonal antibody (RANKL inhibitor) administered via subcutaneous injection twice a year; it does not come into contact with or irritate the esophageal mucosa.
B. Teriparatide: A recombinant parathyroid hormone analogue administered via daily subcutaneous injection; it does not cause esophageal ulceration.
D. Zoledronic acid: An intravenous bisphosphonate administered once yearly; because it bypasses the gastrointestinal tract entirely, it does not cause local upper GI mucosal irritation or esophageal ulcers.
A patient was started on codeine 15 mg orally as needed for postoperative pain. One day after starting codeine, the patient presents to the Emergency Department with confusion, headache and shortness of breath.
Exam pearl: Oral bisphosphonates (e.g., alendronate) → esophagitis and esophageal ulcers.
A patient was started on codeine 15 mg orally as needed for postoperative pain. One day after starting codeine, the patient presents to the Emergency Department with confusion, headache and shortness of breath.
Which of the following most likely describes the patient's gentotype?
A. slow metabolizer of CYP 2D6
B. slow metabolizer of CYP 2C9
C. rapid metabolizer of CYP 2C9
D. rapid metabolizer of CYP 2D6
The correct answer is D. rapid metabolizer of CYP 2D6.
Key Clinical Explanation
Metabolism of Codeine: Codeine is a prodrug that relies on activation by the cytochrome P450 enzyme CYP2D6 to convert into its active metabolite, morphine, which delivers its analgesic effect.
CYP2D6 Ultrarapid/Rapid Metabolizers:
Patients who possess multiple functional gene copies or high-activity alleles of CYP2D6 are rapid (or ultrarapid) metabolizers.
In these individuals, codeine is converted into morphine much faster and in far greater amounts than expected, even at standard therapeutic doses (such as 15 mg).
This rapid accumulation of morphine leads to opioid toxicity / overdose symptoms, including central nervous system depression (confusion, headache) and respiratory depression (shortness of breath, decreased breathing rate).
Explanation of Incorrect Options
A. Slow metabolizer of CYP 2D6: A poor or slow metabolizer converts very little codeine into morphine, leading to lack of therapeutic efficacy (poor pain relief) rather than toxicity.
B & C. Slow / Rapid metabolizer of CYP 2C9: CYP2C9 is not the primary enzyme involved in the bioactivation of codeine to morphine (it metabolizes drugs like warfarin, phenytoin, and NSAIDs).
Exam pearl: Codeine + CYP2D6 ultrarapid metabolizer → increased morphine formation → respiratory depression.
Clinical note: Shortness of breath with confusion after codeine use requires immediate assessment for opioid toxicity and respiratory compromise.
Which of the following infections is prevented with the administration of 0.5% erythromycin eye ointment in newly born infants?
A. mycoplasmal conjunctivitis
B. adenoviral conjunctivitis
C. gonococcal opthalmia
D. chlamydial Infection
The correct answer is C. gonococcal opthalmia.
Key Clinical Explanation
Indication and FDA Approval: 0.5% Erythromycin ophthalmic ointment is administered routinely to all newborns shortly after delivery primarily for the prophylaxis of gonococcal ophthalmia neonatorum (caused by Neisseria gonorrhoeae).
Prevention of Blindness: N. gonorrhoeae ocular infection in neonates can cause severe hyperacute purulent conjunctivitis, corneal ulceration, perforation, and permanent blindness if not prevented.
Effectiveness vs. Chlamydia: Although topical macrolides (such as erythromycin) were historically thought to protect against Chlamydia trachomatis conjunctivitis, clinical evidence and guidelines (including the CDC and USPSTF) demonstrate that topical erythromycin ointment does not reliably prevent neonatal chlamydial conjunctivitis or systemic infection (which requires oral/systemic macrolide therapy if contracted).
Explanation of Incorrect Options
A. Mycoplasmal conjunctivitis: Mycoplasma is not a primary cause of ophthalmia neonatorum and is not the target of routine neonatal ocular prophylaxis.
B. Adenoviral conjunctivitis: Adenovirus is a viral pathogen; antibacterial ointments like erythromycin are ineffective against viral infections.
D. Chlamydial infection: Routine topical erythromycin ocular prophylaxis fails to effectively prevent neonatal chlamydial ophthalmia neonatorum or nasopharyngeal colonization/pneumonia. Systemic therapy is required for C. trachomatis treatment.
Exam pearl: Newborn + erythromycin 0.5% eye ointment → prevention of gonococcal ophthalmia neonatorum.
Prepare for Pharmacy Exams with High-Yield Clinical Pharmacy MCQs
Keep practicing these Clinical Pharmacy and Pharmacology MCQs to strengthen your clinical knowledge and improve your exam performance. Review the correct answers, understand the rationale behind each option, and revise important drug interactions, adverse effects, pharmacogenetics, and patient counseling points.
Visit seenqaaf.blogspot.com for more pharmacy MCQs, hospital pharmacist mock tests, pharmacology revision notes, and licensing exam preparation resources.
Related Keywords: Clinical Pharmacy MCQs, Hospital Pharmacist Exam Questions, Pharmacotherapy MCQs, Pharmacy Licensing Exam Preparation, Clinical Pharmacy Questions and Answers, NAPLEX Practice Questions, Hospital Pharmacy MCQs, Drug Therapy Questions, Pharmacy Exam Preparation, DHA MOH Prometric Exam Preparation.
0 Comments